Abstract
Background: Pediatric endocrine practices had to rapidly transition to telemedicine care at the onset of the novel coronavirus disease 2019 (COVID-19) pandemic. For many, it was an abrupt introduction to providing virtual healthcare, with concerns related to quality of patient care, patient privacy, productivity, and compensation, as workflows had to change. Summary: The review summarizes the common adaptations for telemedicine during the pandemic with respect to the practice of pediatric endocrinology and discusses the benefits and potential barriers to telemedicine. Key Messages: With adjustments to practice, telemedicine has allowed providers to deliver care to their patients during the COVID-19 pandemic. The broader implementation of telemedicine in pediatric endocrinology practice has the potential for expanding patient access. Research assessing the impact of telemedicine on patient care outcomes in those with pediatric endocrinology conditions will be necessary to justify its continued use beyond the COVID-19 pandemic.
References
1.
Burke
BL
, Hall
RW
; Section on Telehealth Care
. Telemedicine: pediatric applications
. Pediatrics
. 2015 Jul
;136
(1
):e293
–308
.2.
Ray
KN
, Ashcraft
LE
, Mehrotra
A
, Miller
E
, Kahn
JM
. Family perspectives on telemedicine for pediatric subspecialty care
. Telemed J E Health
. 2017
;23
(10
):852
–62
. .3.
Casares
M
, Wombles
C
, Skinner
HJ
, Westerveld
M
, Gireesh
ED
. Telehealth perceptions in patients with epilepsy and providers during the COVID-19 pandemic
. Epilepsy Behav
. 2020 Sep
;112
:107394
. .4.
Cabana
MD
, Menard-Livingston
L
. Will telemedicine be the Blockbuster or Netflix of healthcare?
Medpage Today
. 2020
. Available from: https://www.medpagetoday.com/practicemanagement/telehealth/87662.5.
Endocrine Society [Internet]. Summary of Key Provisions of the COVID-19 Public Health Emergency Interim Final Rule Relevant to Endocrinology: Endocrine Society, Hormone Science to Health, document prepared for the Endocrine Society by Cavarocchi Ruscio Dennis Associates. [cited 2020 Aug 28]. Available from: https://www.endocrine.org/-/media/endocrine/files/membership/summary-of-cms-rule-42020.pdf
.6.
Smith
WR
, Atala
AJ
, Terlecki
RP
, Kelly
EE
, Matthews
CA
. Implementation guide for rapid integration of an outpatient telemedicine program during the COVID-19 pandemic
. J Am Coll Surg
. 2020 Aug
;231
(2
):216
–e2
. 7.
Cohen
BH
, Busis
NA
, Ciccarelli
L
. Coding in the world of COVID-19: non-face-to-face evaluation and management care
. Continuum
. 2020 Jun
;26
(3
):785
–98
. .8.
Garg
SK
, Rodbard
D
, Hirsch
IB
, Forlenza
GP
. Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities
. Diabetes Technol Ther
. 2020 Jun
;22
(6
):431
–9
. .9.
Jones
MS
, Goley
AL
, Alexander
BE
, Keller
SB
, Caldwell
MM
, Buse
JB
. Inpatient transition to virtual care during COVID-19 pandemic
. Diabetes Technol Ther
. 2020 Jun
;22
(6
):444
–8
. .10.
Peters
AL
, Garg
SK
. The silver lining to COVID-19: avoiding diabetic ketoacidosis admissions with telehealth
. Diabetes Technol Ther
. 2020 Jun
;22
(6
):449
–53
. .11.
Singh
LG
, Satyarengga
M
, Marcano
I
, Scott
WH
, Pinault
LF
, Feng
Z
, et al. Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: the glucose telemetry system. a randomized clinical trial
. Diabetes Care
. 2020 Nov
;43
(11
):2736
–43
.12.
Korytkowski
M
, Antinori-Lent
K
, Drincic
A
, Hirsch
IB
, McDonnell
ME
, Rushakoff
R
, et al. A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic
. J Clin Endocrinol Metab
. 2020
;105
(9
):dgaa342
. .13.
Philip
M
, Bergenstal
RM
, Close
KL
, Danne
T
, Garg
S
, Heinemann
L
, et al. The digital/virtual diabetes clinic: the future is non-recommendations from an international panel on diabetes digital technologies introduction
. Diabetes Technol Ther
. 2020 Sep 28
. Epub ahead of print
.14.
De Guzman
KR
, Snoswell
CL
, Taylor
ML
, Senanayake
B
, Haydon
HM
, Batch
JA
, et al. A systematic review of pediatric telediabetes service models
. Diabetes Technol Ther
. 2020 Aug
;22
(8
):623
–38
. .15.
D’Anunzio
G
, Maffeis
C
, Cherubini
V
, Rabbone
I
, Scaramuzza
A
, Schiaffini
R
, et al. Caring for children and adolescents with type 1 diabetes mellitus: Italian Society for Pediatric Endocrinology and Diabetology (ISPED) statements during COVID-19 pandemia
. Diabetes Res Clin Pract
. 2020 Aug 20
;168
:108372
.16.
Whittaker
SL
, Adkins
S
, Phillips
R
, Jones
J
, Horsley
MA
, Kelley
G
. Success factors in the long-term sustainability of a telediabetes programme
. J Telemed Telecare
. 2004
;10
(2
):84
–8
. .17.
Su
D
, Michaud
TL
, Estabrooks
P
, Schwab
RJ
, Eiland
LA
, Hansen
G
, et al. Diabetes management through remote patient monitoring: the importance of patient activation and engagement with the technology
. Telemed J E Health
. 2019 Oct
;25
(10
):952
–9
. .18.
Evans
YN
, Golub
S
, Sequeira
GM
, Eisenstein
E
, North
A
. Using telemedicine to reach adolescents during the COVID-19 pandemic
. J Adolesc Health
. 2020 Oct
;67
(4
):469
–71
.19.
American Diabetes Association
. 13. Children and adolescents: standards of medical care in diabetes-2020
. Diabetes Care
. 2020 Jan
;43
(Suppl 1
):S163
–82
. .20.
Donaghue
KC
, Marcovecchio
ML
, Wadwa
RP
, Chew
EY
, Wong
TY
, Calliari
LE
, et al. ISPAD clinical practice consensus guidelines 2018: microvascular and macrovascular complications in children and adolescents
. Pediatr Diabetes
. 2018 Oct
;19
(Suppl 27
):262
–74
. .21.
Avidor
D
, Loewenstein
A
, Waisbourd
M
, Nutman
A
. Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review
. Cost Eff Resour Alloc
. 2020 April
;18
:16
. .22.
Gubitosi-Klug
RA
, Bebu
I
, White
NH
, Malone
J
, Miller
R
, Lorenzi
GM
, et al. Screening eye exams in youth with type 1 diabetes under 18 years of age: once may be enough?
Pediatr Diabetes
. 2019 Sep
;20
(6
):743
–9
.23.
Flynn
JT
, Kaelber
DC
, Baker-Smith
CM
, Blowey
D
, Carroll
AE
, Daniels
SR
, et al. Subcommittee on screening management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents
. Pediatrics
. 2017 Sep
;140
(3
):e20171904
.24.
de Ferranti
SD
, Steinberger
J
, Ameduri
R
, Baker
A
, Gooding
H
, Kelly
AS
, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association
. Circulation
. 2019 Mar
;139
(13
):e603
–34
. .25.
Omboni
S
, Ferrari
R
. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring
. Curr Hypertens Rep
. 2015 Apr
;17
(4
):535
. .26.
Bergenstal
RM
, Beck
RW
, Close
KL
, Grunberger
G
, Sacks
DB
, Kowalski
A
, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
. Diabetes Care
. 2018 Nov
;41
(11
):2275
–80
. .27.
Zeitler
P
, Arslanian
S
, Fu
J
, Pinhas-Hamiel
O
, Reinehr
T
, Tandon
N
, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth
. Pediatr Diabetes
. 2018 Oct
;19
(Suppl 27
):28
–46
. .28.
Davis
AM
, Sampilo
M
, Gallagher
KS
, Dean
K
, Saroja
MB
, Yu
Q
, et al. Treating rural paediatric obesity through telemedicine vs. telephone: outcomes from a cluster randomized controlled trial
. J Telemed Telecare
. 2016 Mar
;22
(2
):86
–95
. .29.
Davis
AM
, James
RL
, Boles
RE
, Goetz
JR
, Belmont
J
, Malone
B
. The use of TeleMedicine in the treatment of paediatric obesity: feasibility and acceptability
. Matern Child Nutr
. 2011 Jan
;7
(1
):71
–9
. .30.
Schiel
R
, Beltschikow
W
, Radón
S
, Kramer
G
, Schmiedel
R
, Berndt
RD
, et al. Long-term treatment of obese children and adolescents using a telemedicine support programme
. J Telemed Telecare
. 2008
;14
(1
):13
–6
. .31.
Ohri-Vachaspati
P
, Acciai
F
, DeLia
D
, Lloyd
K
, Yedidia
MJ
. Accuracy of parent-measured and parent-estimated heights and weights in determining child weight status
. JAMA Pediatr
. 2019 Jun
;173
(8
):1
–3
.32.
Center for Disease Control Public Health Media Library [Internet]. Measuring Children’s Height and Weight Accurately At Home. [cited Sept 4, 2020]. Available from: https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/measuring_children.html/#Height
.33.
Campisi
SC
, Marchand
JD
, Siddiqui
FJ
, Islam
M
, Bhutta
ZA
, Palmert
MR
. Can we rely on adolescents to self-assess puberty stage? A systematic review and meta-analysis
. J Clin Endocrinol Metab
. 2020 Aug
;105
(8
):dgaa135
. .34.
Rasmussen
AR
, Wohlfahrt-Veje
C
, Tefre de Renzy-Martin
K
, Hagen
CP
, Tinggaard
J
, Mouritsen
A
, et al. Validity of self-assessment of pubertal maturation
. Pediatrics
. 2015 Jan
;135
(1
):86
–93
. .35.
Gibelli
G
, Gibelli
B
, Nani
F
. Thyroid cancer: possible role of telemedicine
. Acta Otorhinolaryngol Ital
. 2008 Dec
;28
(6
):281
–6
..36.
Hofman
LF
, Foley
TP
Jr, Henry
JJ
, Naylor
EW
. Assays for thyroid-stimulating hormone using dried blood spotted filter paper specimens to screen for hypothyroidism in older children and adults
. J Med Screen
. 2003
;10
(1
):5
–10
. .37.
Goodman
NF
, Cobin
RH
, Futterweit
W
, Glueck
JS
, Legro
RS
, Carmina
E
. American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome: part 2
. Endocr Pract
. 2015 Dec
;21
(12
):1415
–26
.38.
Kansra
AR
, Menon
S
. PCOS: perspectives from a pediatric endocrinologist and a pediatric gynecologist
. Curr Probl Pediatr Adolesc Health Care
. 2013 May–Jun
;43
(5
):104
–13
. .39.
Rohayem
J
, Nieschlag
E
, Kliesch
S
, Zitzmann
M
, Inhibin
B
. Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation between constitutional delay of growth and puberty and hypogonadotropic hypogonadism
. Andrology
. 2015 Sep
;3
(5
):882
–7
. .40.
Harrington
J
, Palmert
MR
. Clinical review: distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests
. J Clin Endocrinol Metab
. 2012 Sep
;97
(9
):3056
–67
. .41.
Wei
C
, Crowne
EC
. Recent advances in the understanding and management of delayed puberty
. Arch Dis Child
. 2016 May
;101
(5
):481
–8
. .42.
Lewis
KA
, Goldyn
AK
, West
KW
, Eugster
EA
. A single histrelin implant is effective for 2 years for treatment of central precocious puberty
. J Pediatr
. 2013 Oct
;163
(4
):1214
–6
. .43.
Grote
FK
, Oostdijk
W
, De Muinck Keizer-Schrama
SM
, van Dommelen
P
, van Buuren
S
, Dekker
FW
, et al. The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines
. BMC Pediatr
. 2008 May
;8
:21
. .44.
Hembree
WC
, Cohen-Kettenis
PT
, Gooren
L
, Hannema
SE
, Meyer
WJ
, Murad
MH
, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline
. J Clin Endocrinol Metab
. 2017 Nov
;102
(11
):3869
–903
. .45.
Speiser
PW
, Arlt
W
, Auchus
RJ
, Baskin
LS
, Conway
GS
, Merke
DP
, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline
. J Clin Endocrinol Metab
. 2018 Nov
;103
(11
):4043
–88
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
